Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glucoferro is an oral iron supplement containing ferrous gluconate, developed and marketed by Guidotti, a subsidiary of the Menarini Group. It is primarily indicated for the treatment of iron deficiency and iron-deficiency anemia. The medication provides elemental iron in the ferrous (Fe2+) state, which is a critical component of hemoglobin, myoglobin, and various enzymes. By replenishing iron stores, Glucoferro facilitates the production of red blood cells and improves oxygen transport capacity in the blood. It is typically administered orally and is valued for its gastrointestinal tolerability compared to some other iron salts. The product is available in formulations such as effervescent tablets and oral solutions to enhance patient compliance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Glucoferro.